XTRA:EVTLife Sciences
Evotec (XTRA:EVT) Valuation Check After Revenue Beat And New Horizon Transformation Plan
Evotec (XTRA:EVT) has drawn fresh attention after beating its full-year 2025 revenue expectations and unveiling its Horizon transformation plan, a new mid term framework aimed at refocusing drug discovery and development efforts.
See our latest analysis for Evotec.
Despite the Horizon announcement and revenue beat, sentiment has been weak, with a 30 day share price return of 30.19% decline and a 1 year total shareholder return of 29.86% loss, indicating fading momentum.
If this shift in...